ATR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AptarGroup Inc (ATR) is not a strong buy for a beginner investor seeking long-term growth at this time. While the company has a strong balance sheet and exposure to the defensive pharma sector, the technical indicators are bearish, recent financial performance shows declining profitability, and there are no strong positive catalysts or trading signals to support immediate entry. Holding or waiting for better entry points is recommended.
The technical indicators are bearish. The MACD is negatively expanding, RSI is neutral at 32.086, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 124.508), with resistance at R1: 131.965.
Wells Fargo upgraded the stock to Overweight with a price target of $144, citing a strong balance sheet and defensive pharma exposure. The stock has a 40% chance of increasing 2.7% in the next month.
Recent financial performance shows declining net income (-26.35% YoY), EPS (-23.65% YoY), and gross margin (-12.01% YoY). The MACD and moving averages indicate a bearish trend, and there are no recent news catalysts or significant insider/hedge fund activity.
In 2025/Q4, revenue increased by 13.52% YoY to $962.7M, but net income dropped by 26.35% YoY to $74.34M. EPS decreased by 23.65% YoY to 1.13, and gross margin fell by 12.01% YoY to 27.18%.
Analysts are mixed. Wells Fargo upgraded the stock to Overweight with a $144 price target, citing defensive pharma exposure. BofA maintained a Neutral rating with a price target of $145, slightly lowered from $147. Baird raised its price target to $156, citing improved earnings visibility.
